Last reviewed · How we verify
Almonertinib combined with SHR-1701 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Almonertinib combined with SHR-1701 (Almonertinib combined with SHR-1701) — Suzhou Suncadia Biopharmaceuticals Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Almonertinib combined with SHR-1701 TARGET | Almonertinib combined with SHR-1701 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Almonertinib combined with SHR-1701 CI watch — RSS
- Almonertinib combined with SHR-1701 CI watch — Atom
- Almonertinib combined with SHR-1701 CI watch — JSON
- Almonertinib combined with SHR-1701 alone — RSS
Cite this brief
Drug Landscape (2026). Almonertinib combined with SHR-1701 — Competitive Intelligence Brief. https://druglandscape.com/ci/almonertinib-combined-with-shr-1701. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab